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Abstract 
Dementia with Lewy bodies (DLB) and Parkinson’s Disease (PD) are neurodegenerative disorders of the aging population 
characterized by the abnormal accumulation of alpha-synuclein (alpha-syn). Previous studies have suggested that 
excitotoxicity may contribute to neurodegeneration in these disorders, however the underlying mechanisms and their 
relationship to alpha-syn remain unclear. For this study we proposed that accumulation of alpha-syn might result in 
alterations in metabotropic glutamate receptors (mGluR), particularly mGluR5 which has been linked to deficits in murine 
models of PD. In this context, levels of mGluR5 were analyzed in the brains of PD and DLB human cases and alpha-syn 
transgenic (tg) mice and compared to age-matched, unimpaired controls, we report a 40% increase in the levels of mGluR5 
and beta-arrestin immunoreactivity in the frontal cortex, hippocampus and putamen in DLB cases and in the putamen in PD 
cases. In the hippocampus, mGluR5 was more abundant in the CA3 region and co-localized with alpha-syn aggregates. 
Similarly, in the hippocampus and basal ganglia of alpha-syn tg mice, levels of mGluR5 were increased and mGluR5 and 
alpha-syn were co-localized and co-immunoprecipated, suggesting that alpha-syn interferes with mGluR5 trafficking. The 
increased levels of mGluR5 were accompanied by a concomitant increase in the activation of downstream signaling 
components including ERK, Elk-1 and CREB. Consistent with the increased accumulation of alpha-syn and alterations in 
mGluR5 in cognitive- and motor-associated brain regions, these mice displayed impaired performance in the water maze 
and pole test, these behavioral alterations were reversed with the mGluR5 antagonist, MPEP. Taken together the results 
from study suggest that mGluR5 may directly interact with alpha-syn resulting in its over activation and that this over 
activation may contribute to excitotoxic cell death in select neuronal regions. These results highlight the therapeutic 
importance of mGluR5 antagonists in alpha-synucleinopathies. 
Citation: Price DL, Rockenstein E, Ubhi K, Phung V, MacLean-Lewis N, et al. (2010) Alterations in mGluR5 Expression and Signaling in Lewy Body Disease and in 
Transgenic Models of Alpha-Synucleinopathy – Implications for Excitotoxicity. PLoS ONE 5(11): e14020. doi:10.1371/journal.pone.0014020 
Editor: Hitoshi Okazawa, Tokyo Medical and Dental University, Japan 
Received July 4, 2010; Accepted October 19, 2010; Published November 16, 2010 
Copyright: © 2010 Price et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
Funding: This work was supported by The Branfman Family and MJ Fox Foundations, National Center for Research Resources RR004050, National Institute on 
Deafness and Other Communication Disorders DC03192 (CCDB), RR043050 (Mouse BIRN), National Institute on Aging AG18840, AG022074, AG10435 and National 
Institutes of Health LM07292. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 
Competing Interests: The authors have declared that no competing interests exist. 
* E-mail: emasliah@ucsd.edu 
¤ Current address: ACADIA Pharmaceuticals Inc., San Diego, California, United States of America 
Introduction 
Movement disorders with parkinsonism and cognitive impair­
ment continue to be a significant neurological problem in the 
aging population. While patients with classical Parkinson’s Disease 
(PD) present with tremor, motor deficits and autonomic 
dysfunction(s), others patients develop cognitive alterations 
including dementia. Patients that present first with cognitive 
impairments followed by development of parkinsonism are 
denominated dementia with Lewy bodies (DLB) to distinguish 
them from patients with PD dementia (PDD). Jointly this 
heterogeneous group of disorders is referred to as Lewy body 
disease (LBD) [1]. These conditions are associated with progressive 
and selective loss of dopaminergic and non-dopaminergic cells [2] 
and the formation of Lewy bodies (LBs) and Lewy neurites 
containing fibrillar alpha-synuclein (alpha-syn) [3,4,5,6,7,8] in 
cortical and subcortical regions [9,10,11]. Previous studies have 
suggested that excitotoxicity may contribute to neurodegeneration 
in these disorders however the underlying mechanisms and their 
relationship to alpha-syn remain unclear. 
Synucleins are a family of related proteins including alpha-, 
beta-, and gamma-synuclein. Alpha-syn is a 14 kDa ’naturally 
unfolded protein’ [12,13] abundant at the presynaptic terminal 
[14] and likely plays a role in modulating vesicular synaptic release 
[15]. Abnormal accumulation of alpha-syn is thought to be 
centrally involved in the pathogenesis of both sporadic and 
inherited forms of parkinsonism as mutations and multiplications 
in the alpha-syn gene have been associated with rare familial forms 
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of PD [4,8,16]. In addition, over expression of alpha-syn in 
transgenic (tg) mice [17,18,19] and Drosophila [20] recreates several 
pathological and dysfunctional motor performance features of PD. 
Recent studies have shown that accumulation of oligomeric, rather 
than polymeric (fibrilar) forms of alpha-syn in the synapses and 
axons may be responsible for neuronal dysfunction and degener­
ation [21,22,23]. 
In addition to the modulation of vesicular synaptic release, 
alpha-syn has been shown to regulate dopaminergic neurotrans­
mission (reviewed by [24]) and to be involved in dopamine release 
[25,26] whilst dopamine in turn, has been reported to promote 
alpha-syn oligomerization [27,28]. These interactions between 
dopamine and alpha-syn may help explain the selective vulner­
ability of the dopaminergic system in PD. Recent studies have 
demonstrated that, in addition to well-documented dopaminergic 
alterations, other neurotransmitter systems are also dysregulated in 
PD and DLB. For example, altered glutamatergic neurotransmis­
sion within basal ganglia circuitry is thought to contribute to the 
clinical presentation of parkinsonian-related motor symptoms, 
though the mechanisms underlying this are not yet fully 
understood. Abnormal activation of group I metabotropic 
receptors (mGluR1 and mGluR5) within the basal ganglia 
circuitry has been proposed to account for cognitive and motor 
alterations in patients with DLB [29,30,31]. mGluR5 in particular 
has attracted considerable interest because of its potential 
involvement in Alzheimer’s Disease (AD) [32] and PD [33,34], 
its role in learning and memory [35,36], and its abundant 
expression in the frontal cortex, limbic system, and caudoputamen 
[37]—brain regions selectively affected in AD and PD. 
Further support for a role of group I mGluR receptors in the 
pathogenesis of PD and DLB steams from studies showing that 
mGluR5 antagonists ameliorate the behavioral alterations in 
animal model of parkinsonism [38,39,40,41] and are neuropro­
tective against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyr­
idine) neurotoxicity in animals [42,43]. Mice lacking the mGluR5 
receptors also display reduced MPTP toxicity [43]. 
Although extensive behavioral pharmacology studies with 
mGluR5 antagonists in PD-like animal models have been 
performed, surprisingly very limited information is available as 
to the potential role of alterations in mGluR’s in the pathogenesis 
of the excitotoxicity in PD or DLB patients, or alpha-syn tg animal 
models. Here we describe studies of mGluR5 expression the brains 
of patients with DLB or PD and in alpha-syn over-expressing tg 
mice, and discuss a role for altered mGluR5 expression in 
excitotoxicity. Furthermore, we present evidence that mGluR5 
receptor antagonism is capable of ameliorating the behavioral 
deficits observed in alpha-syn tg mice. Taken together these results 
support the notion that mGluRs play an important role in the 
pathogenesis of disorders with alpha-syn accumulation and that 
mGluR5 receptors may be an important target for therapeutic 
intervention. 
Materials and Methods 
Human specimens, Neuropathological Evaluation and 
Criteria for diagnosis 
A total of 24 cases (n = 8 non-demented controls; n = 8 DLB and 
n = 8 PD cases) were included for the present study. Autopsy 
material was obtained from patients (Table 1) studied neurolog­
ically and psychometrically at the Alzheimer Disease Research 
Center/University of California, San Diego (ADRC/UCSD). The 
last neurobehavioral evaluation was performed within 12 months 
before death and included Blessed score, Mini Mental State 
Examination (MMSE) and dementia-rating scale (DRS) [44,45]. 
Brains were processed and evaluated according to standard 
methods [46]. At autopsy, brains were divided sagitally, the left 
hemibrain was fixed in formalin of 4% paraformaldehyde (PFA) 
for neuropathological analysis and the right frozen at 270uC for 
subsequent neurochemical analysis. Paraffin sections from 10% 
buffered formalin-fixed neocortical, limbic system and subcortical 
material stained with hematoxylin and eosin (H&E), thioflavine-S, 
ubiquitin (Dako, Carpinteria, CA) and a-syn (Millipore, Teme­
cula, CA) were used for routine neuropathological analysis that 
included assessment of plaques, tangles, Lewy bodies and Braak 
stage [46]. The diagnosis of DLB was based in the initial clinical 
presentation with dementia followed by parkinsonism and the 
presence of alpha-syn and ubiquitin-positive LBs in cortical and 
subcortical regions [47,48]. The diagnosis of PD was based on the 
initial presentation with parkinsonism and presence of alpha-syn 
and ubiquitin positive LBs in subcortical regions. 
Transgenic mouse lines 
Transgenic mice over expressing wildtype human (h) alpha-syn 
under the control of the platelet-derived growth factor (PDGF) (D-
line; [19]) and the mThy1 (line 61; [49]) promoters were used. The 
PDGF-alpha-syn tg mice were selected because they display 
accumulation of a-syn in the frontal cortex and limbic system 
similar to DLB accompanied by behavioral deficits, early motor 
alterations, loss of dopaminergic terminals and formation of 
inclusion bodies [19]. The mThy1-alpha-syn tg mice were selected 
because they display more extensive a-syn accumulation in the 
frontal cortex, limbic system and subcortical regions including the 
basal ganglia and the substantia nigra. For the immunoblot and 
immunochemical studies a total of 24 mice were used (n = 8 non­
tg; n = 8 PDGF-alpha-syn and n = 8 mThy1-alpha-syn tg) age 6 
months old. For the behavioral and therapeutic studies a total of 
36 animals were utilized (n = 12 non-tg; n = 12 PDGF-alpha-syn 
and n = 12 mThy1-alpha-syn tg) at 9 months of age. From each of 
the groups half of the mice (n = 6) were treated with vehicle only 
and the other half (n = 6) were treated with MPEP (2-Methyl-6­
(phenylethynyl)-pyridine). 
Treatment with mGluR5 antagonist and Behavioral 
testing 
For these experiments MPEP, a selective and systemically active 
mGluR5 receptor antagonist, was used to test the effects of 
mGluR5 receptor antagonism on behavioral performance [50]. 
MPEP HCl was obtained from Tocris Biosciences (Ellisville, MO; 
Catalog #1212), and dissolved in 0.9% saline solution at a dose of 
20 mg/ml. This dose was chosen based on reports in the literature 
demonstrating effective dose ranges for behavioral studies in mice 
without adverse effects [51,52]. The MPEP solution was sonicated 
to ensure complete dilution and the solution was used the same 
day. MPEP was administered by intraperitoneal (IP) injection, the 
animals were weighed on the day of testing and the appropriate 
volume was determined and recorded for each animal (approx­
imately 0.2 ml/animal). A 30-minute pre-injection time was used, 
and administration times were staggered to account for this time 
prior to testing. The behavioral effects of MPEP in the a-syn over-
expressing tg mice were tested in the vertical pole test (motor test) 
and the Morris water maze (learning and memory test). 
The pole test was divided into 3 phases, including a pretest (with 
saline injection), a challenge with MPEP administration, and a 
reassessment (no injections) to determine performance one week 
after MPEP administration. The percentage change in perfor­
mance from Test 1 to Test 2 was determined by calculating the 
difference between success ratios on these two separate test days. 
Animals underwent testing on a vertical pole apparatus to evaluate 
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Table 1. Summary of clinical neurobehavioral and post-mortem features for human samples. 
Age PMT Brain weight LBs 
(years, Gender (hours, Braak Blessed score (grams, neocortex LBs midbrain 
Group N mean ± SEM) M/F mean ± SEM) stage (mean ± SEM) mean ± SEM) (score) (score) 
Control 8 76 (610) 2/3 8 (63) 0 0 1200 (697) 0 0 
Dementia with Lewy 
bodies 
8  83  (65) 4/1 9 (62) III-IV 28 (63) 1216 (685) 3+ 2+ 
Parkinson’s Disease 8 77 (68) 3/2 6 (62) 0 5 (62) 1276 (6128) 0 3+ 
LBs = Lewy bodies; PMT = postmortem time, SEM = standard error of the mean. 
doi:10.1371/journal.pone.0014020.t001 
their ability to negotiate and descend the apparatus. The testing 
procedures were derived from previous reports [53,54]. The 
apparatus consists of a rough-surfaced pole (diameter 1 cm; height 
50 cm) inserted perpendicular to a circular platform. The pole was 
lightly roughened with medium grade sandpaper in between 
animals to ensure that all animals were presented with a 
comparable pole surface. The circular platform was covered with 
multilayered padding to avoid injury to the animals in the event of 
a fall from the apparatus. The top padded surface was disposable 
and frequently changed to avoid a soiled surface. Non-tg mice 
easily complete this task, and to date, our group has noted 
performance deficits in the alpha-syn tg mice as early as 4 months 
of age. The pole testing session consisted of 2 training trials 
followed by 5 test trials (7 trials total). The first 2 untimed trials 
served to acquaint the animal with the apparatus. The 5 test trials 
were timed to a maximum of 120 sec. Two timed measures were 
recorded including: (1) the time until the animal completely turned 
around and re-oriented towards platform base (T-Turn), and (2) 
the total time spent on apparatus (T-Total). This procedure was 
repeated a total of 5 times. The ratio of success for each subject 
based on the number of times (out of 5 total trials) the apparatus 
was successfully negotiated was noted. 
To evaluate the effects of MPEP on learning and memory in the 
alpha-syn over-expressing tg mice they were tested in the Morris 
water maze as previously described [55]. Mice were treated for 28 
days with saline vehicle solution of MPEP as a daily IP injection 
(20 mg/ml, 0.2 ml per animal per day). At day 20 of the 
treatments mice were tested in the water maze for 8 days. For this 
purpose a pool (diameter 180 cm) was filled with opaque water 
(24uC) and mice were first trained to locate a visible platform (days 
1–3) and then a submerged hidden platform (days 4–7) in three 
daily trials 2–3 min apart. Mice that failed to find the hidden 
platform within 90 seconds were placed on it for 30 seconds. The 
same platform location was used for all sessions and all mice. The 
starting point at which each mouse was placed into the water was 
changed randomly between two alternative entry points located at 
a similar distance from the platform. On day 7, another visible 
platform trial was performed to exclude differences in motivation 
and fatigue. On day 8 the platform was removed (probe test) and 
mice were tested to evaluate the numbers of entrances and time 
expended in the target quadrant. Time to reach the platform 
(latency), path length, and swim speed were recorded with a 
Noldus Instruments EthoVision video tracking system (San Diego 
Instruments, San Diego, CA) set to analyze two samples per 
second. UCSD is an Institutional Animal Care and Use 
Committee accredited institution and the UCSD Animal Subjects 
Committee approved the experimental protocol followed in all 
studies according to the Association for Assessment and Accred­
itation of Laboratory Animal Care International guidelines. 
Immunoblot analysis 
The immunoblot procedures for human and transgenic mouse 
samples were performed as previously described [19]. Briefly, 
dissected frozen tissues were homogenized, and processed and 
separated into cytosolic and particulate fractions. The nuclear 
fraction was obtained by resuspending the pellet (from the 
5000 g spin after homogenization) in buffer +1%SDS +1% 
TritonX. Incubated on ice for 15 minutes, vortexing every 3 
minutes, then centrifuged for 10 minutes at 14,000 g at 4uC. 
The protein concentrations of individual samples were deter­
mined using a BCA protein assay kit (Pierce Biotechnology, 
Rockford, IL). Approximately 20 ug of each fraction were 
loaded onto either 3–8% Tris-acetate (mGluR5 human) or 4– 
12% Bis-Tris (all others) SDS polyacrylamide gel electrophoresis 
(SDS/PAGE) gels (Invitrogen, Carlsbad, CA), transferred into 
Immobilon membranes (Millipore, Temecula, CA), blocked with 
either 3% BSA (for animal samples) or 5% Milk/1% BSA (for 
human samples) in PBS, and incubated overnight at 4uC with  
antibodies against mGluR5 (rabbit polyclonal, 1:1000, Milli­
pore, Temecula, CA), beta-arrestin (rabbit polyclonal, 1:1000, 
Cell Signaling, Boston, MA), extracellular signal-regulated 
kinase (ERK, mouse monoclonal, 1:1000, Cell Signaling, 
Boston, MA), phospho-ERK (pERK, mouse monoclonal, 
1:1000 Cell Signaling, Boston, MA), Elk-1 member of ETS 
oncogene family (Elk-1, rabbit polyclonal, 1:1000, Cell Signal­
ing, Boston, MA, phospho-Elk-1 (pElk-1, rabbit polyclonal, 
1:1000, Cell Signalling, Boston, MA), cAMP response element-
binding (CREB, mouse monoclonal, 1:1000 Cell Signaling, 
Boston, MA) and phospho-CREB (pCREB, rabbit polyclonal, 
1:1000 Cell Signaling, Boston, MA). The next day, blots were 
rinsed several times and incubated with the appropriate 
secondary antibody on a shaker for 1 hour at room temperature. 
Membranes were processed using a chemiluminescence kit 
(Western Lightning Chemiluminescence Reagent Plus; Perkin 
Elmer, Boston, MA) and imaged using a Versadoc system 
(Biorad, Hercules, CA). Following imaging, the membranes were 
processed for further immunolabeling using an antibody re-
probing kit (Chemicon, Temecula, CA). Actin loads (Beta-actin, 
mouse monoclonal, Sigma, St. Louis, MO) were then deter­
mined for each membrane as a control for protein loading. All 
mGluR5 protein levels were normalized using the actin 
immunoreactivity values. The Quality OneTM image analysis 
program (Biorad, Hercules, CA) was used for quantitative 
assessment of bands. Statistical analyses were performed using 
one-way ANOVAs and the level for significance set at p,0.05. 
Resultant data were graphed using SigmaPlot 9.0 (Systat 
Software Inc., Richmond, CA). Graphed data are presented as 
the mean optical density (group means mGluR5/actin immu­
nolevels) 6 the standard error of the mean (SEM). 
PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e14020 
mGluR5 in A-Synucleinopathy 
Tissue processing, immunocytochemical analysis and 
laser scanning confocal microsocopy 
Briefly, as previously described [56], free-floating 40 mm thick 
vibratome sections were washed with Tris buffered saline (TBS, 
pH 7.4), pre-treated in 3% H2O2, and blocked with 10% serum 
(Vector Laboratories, Burlingame, CA), 3% bovine serum 
albumin (Sigma), and 0.2% gelatin in TBS-Tween (TBS-T). For 
human brains, sections from the frontal cortex, hippocampus and 
putamen were used; for the mice sagittal sections from the 
complete brain were studied. Sections were incubated at 4uC 
overnight with the monoclonal antibodies against mGluR5 
(Millipore) and beta-arrestin (Cell Signaling) or the polyclonal 
antibody against a-syn (Millipore). Sectionswere then incubated in 
secondary antibody (1:75, Vector), followed by Avidin D 
horseradish peroxidase (HRP, ABC Elite, Vector) and reacted 
with diaminobenzidine (DAB, 0.2 mg/ml) in 50 mM Tris 
(pH 7.4) with 0.001% H2O2. Control experiments consisted of 
incubation with pre-immune rabbit serum. To investigate the 
effects of postmortem delay and fixation on the levels of mGluR5 
immunoreactivity, preliminary studies were performed in a subset 
of cases (n = 5) with postmortem delay ranging from 4–48 h. 
Immunostained sections were imaged with a digital Olympus 
microscope and assessment of levels of mGluR5 and arrestin 
immunoreactivity was performed utilizing the Image-Pro Plus 
program (Media Cybernetics, Silver Spring, MD). For each case a 
total of three sections (10 digital images per section at 400x) were 
analyzed in order to estimate the average number of immunola­
beled cells per unit area (mm2) and the average intensity of the 
immunostaining (corrected optical density). 
Double-immunocytochemical analyses was performed utilizing 
the Tyramide Signal AmplificationTM-Direct (Red) system (NEN 
Life Sciences, Boston, MA) to detect alpha-syn. Specificity of this 
system was tested by deleting each primary antibody. For this 
purpose, sections were double-labeled with the monoclonal 
antibodies against alpha-syn (1:20,000, Millipore) detected with 
Tyramide Red, and mGluR5 detected with fluorescein isothiocy­
anate (FITC)-conjugated secondary antibodies (1:75, Vector). All 
sections were processed simultaneously under the same conditions 
and experiments were performed twice for reproducibility. 
Sections were imaged with laser scanning confocal microscope 
BioRad Radiance 2000 (Hercules, CA) equipped with a Nikon 
E600FN Ellipse microscope (Japan) and using a Nikon Plan Apo 
60x oil objective (NA 1.4; oil immersion). 
Tissue section acquisition and immunocytochemistry for 
large scale mosaic 
An additional group of non-tg and PDGF- alpha-syn tg mice 
(n = 6 per group; 6 month old) were deeply anesthetized with 
NembutalTM (pentobarbital) and perfused via intracardiac cath­
eterization. Perfusion with oxygenated Ringer’s solution contain­
ing 250 U/ml heparin, 0.2 mg/ml xylocaine and 1% dextrose was 
followed 4% paraformadehyde in 0.1 M phosphate buffer solution 
(PBS) (both at 37 degrees Celsius). The brains were carefully 
removed from the skull and postfixed for 1 hour in the same 
fixative used in the perfusion. The brain was blocked and cut into 
2 mm thick sections using an acrylic brain matrix (David Kopf; 
Tujunga, CA) to facilitate reproducibility of sections. These thick 
sections were then sectioned into 80 micron thick coronal sections 
using a Vibratome (VT1000E, Leica Microsystems, Wetzlar, 
Germany). 
Tissue sections were incubated with monoclonal anti-a-syn 
(1:250; BD Transduction Laboratories, San Diego, CA) and rabbit 
anti-mGluR5 (1:250; Millipore, Temecula, CA) followed by 
incubation with donkey anti-mouse Alexa Red (1:100, Molecular 
Probes, Carlsbad, CA) and donkey anti-rabbit FITC (1:100, 
Jackson Immunoresearch Laboratories, Inc., West Grove, PA, 
USA) overnight at 4C. The immunolabeling procedure consisted 
of the following steps: (1) 665 min rinses in 0.1 M PBS; (2) 1 hr 
blocking step in PBS containing 3% normal donkey (NDS), 0.1% 
Triton X-100, 1% fish gelatin, and 1% BSA; (3) 48 hr incubation 
in primary antibodies diluted in working buffer (PBS, 1% NDS) at 
20 degrees C; (4) 665 minute rinsed in working buffer; (5) 24 hr 
incubation in working buffer containing donkey anti-mouse Alexa 
Fluor 488 (Molecular Probes, Carlsbad, CA) and donkey anti-
rabbit RRX (Jackson Immunoresearch Laboratories, Inc., West 
Grove, PA, USA). (6) 6610 min rinses in working buffer; (7) 
3610 min rinses in PBS; (8) the sections were free floated onto 
slides and coverslipped using ProLong mounting media (Invitro­
gen Molecular Probes, Carlsbad, CA) with DAPI nuclear stain. 
Controls for the mGluR5 antibody experiments included both 
preabsorption with the control peptide (Chemicon,Temecula, 
CA), as well as primary omission studies, which both revealed a 
lack of non-specific staining (data not shown). Controls for other 
antibodies used were performed via omission of primary 
antibodies, and revealed no non-specific staining (data not shown). 
All steps were conducted at 4uC, on wet ice and with ice-cold 
solutions. 
Acquisition of large-scale mosaic survey images 
The wide-field mosaic image data sets were acquired with the 
multiphoton scanning system described previously [57,58] and 
these were used to survey brain regions for further targeted 
imaging and analyses. For these purpose, sections double labeled 
with antibodies against mGluR5 and a-syn as described above 
were used. Representative large scale images were acquired using 
a customized video-rate multiphoton microscope [59] equipped 
with a custom automated high precision motorized stage (Applied 
Precision LLC, Issaquah, WA), which allows for the automatic 
acquisition of ultra-large field image mosaics in 2 and 3 
dimensions [57,58]. A Nikon Plan Apo TIRF (6061.45) oil 
immersion objective was used. These mosaic images are acquired 
by rastering the specimen along the X, Y, and Z axes, introducing 
a prescribed amount of overlap between acquired images (in this 
case 10%) to aid alignment. Unprocessed image data acquired on 
the high-speed multiphoton microscope is subsequently stored as a 
single stack of images. The image stack is analyzed using the 
JAVA-based ImageJ, a freely available software package, using 
plugins developed at NCMIR for processing, aligning, and 
assembling these massive datasets. Briefly, each file is separated 
into three separate.tiff stacks, one for each channel. Each tile of the 
image mosaic is normalized to eliminate shading gradients, 
followed by the automatic alignment of individual tiles to form a 
full size mosaic image of the data for each channel. A ‘‘globally 
optimized,’’ normalized cross-correlation algorithm is used to 
achieve sub-pixel alignment accuracy. The assembled mosaics are 
then combined into one full-scale color image. For 3D imaging, 
the process is repeated for each wide field image plane in Z. The 
large-scale images were used to identify regions of interest for 
confocal imaging studies. 
Statistical analyses 
One-way ANOVAs were performed for water maze and pole 
test data using the Statview statistical package (version 5.0.1, Cary, 
NC). Behavioral and image data were graphed using SigmaPlot 
9.0 (Systat Software Inc., Richmond, CA). All data are presented 
as the mean group value 6 the standard error of the mean. The 
criterion for significance was set at p,0.05. 
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Results 
Regionally selective increases in the levels of mGluR5 in 
DLB and PD cases 
Given the abundant expression of mGluR5 in brain regions 
involved in AD and PD such as the frontal cortex, limbic system, 
and caudoputamen [37], it has been proposed that alterations in 
mGluR5 may be involved in the pathogenesis of AD [32] and PD 
[33,34,35,36]. Nonetheless the relative levels of mGluR5 expres­
sion and alterations in DLB or PD have not been studied. For this 
purpose, patterns of distribution for mGluR5 and the downstream 
regulators were evaluated by immunocytochemistry and immu­
noblot analysis. 
mGluR5 immunoreactivity was associated with pyramidal 
neurons in layers 2–3 of the frontal cortex (Figure 1), in pyramidal 
neurons in the CA3 region of the hippocampus and in mid-spiny 
neurons in the caudo-putamen (Figure S1). Compared to control 
cases, in DLB there was a significant increase in the levels of 
mGluR5 immunoreactivity in neurons in the frontal cortex 
(Figure 1A, B, D), hippocampus (Figure S1, A, B, D) and caudo­
putamen region (Figure S1E, F, analyzed in H) Compared to 
controls, in the PD cases, levels of mGluR5 were increased in the 
caudo-putamen (Figure S1E, G, H). However levels in the frontal 
cortex and hippocampus were comparable to controls (frontal 
cortex, Figure 1A, C, D; hippocampus, Figure S1A, C, D). Beta­
arrestin is a downstream regulator of mGluR5 recycling. Group I 
mGluRs undergo rapid internalization after agonist exposure, this 
internalization is strongly inhibited by the expression of both beta­
arrestin and dynamin dominant-negative mutants [60,61,62]. 
Similar to mGluR5, beta-arrestin was associated with pyramidal 
neurons in layers 2–3 of the frontal cortex (Figure 1). Compared to 
controls, beta-arrestin immunoreactivity was increased in the DLB 
cases in the frontal cortex (Figure 1E, F, H). Compared to controls, 
PD cases displayed no differences in beta-arrestin immunoreac­
tivity in the frontal cortex (Figure 1E, G, H). As expected, 
compared to control cases, neocortical alpha-syn levels were much 
higher in DLB and were associated with LBs in these cases as 
opposed to the neuritic, punctate staining observed in the controls 
(Figure 1I, J, L). There was no significant difference in neocortical 
alpha-syn immunoreactivity in the PD cases compared to controls 
(Figure 1I, K, L). 
By immunoblot analysis, mGluR5 was identified in the 
membrane fractions from athe frontal cortex, hippocampus and 
caudate of controls, DLB and PD cases as a double band with an 
Figure 1. Immunohistochemical analysis of mGluR5, beta-arrestin and alpha-syn in the frontal cortex of Control, DLB and PD cases. 
(A, B, C) Representative bright field microscopy images of mGluR5 immunoreactivity in the frontal cortex of control, DLB and PD cases respectively. 
(D) Analysis of mGluR5 immunoreactivity in the frontal cortex of control, DLB and PD cases. (E, F, G) Representative bright field microscopy images of 
beta-arrestin immunoreactivity in the frontal cortex of control, DLB and PD cases respectively. (H) Analysis of beta-arrestin immunoreactivity in the 
frontal cortex of control, DLB and PD cases. (I, J, K) Representative bright field microscopy images of alpha-syn immunoreactivity in the frontal cortex 
of control, DLB and PD cases respectively. (L) Analysis of alpha-syn immunoreactivity in the frontal cortex control, DLB and PD cases. Scale bar 
= 30  mM. * Indicates a significant difference between DLB or PD cases compared to control cases (p,0.05, one-way ANOVA and post hoc Fisher). # 
Indicates a significant difference between DLB and PD cases (p,0.05, one-way ANOVA and post hoc Fisher) (n = 8 cases per group). 
doi:10.1371/journal.pone.0014020.g001 
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approximate MW of 132 kDa (Figure 2A, C and E). Compared to 
controls, in the DLB cases, there was a significant increase in 
mGluR5 levels in the membrane fractions from the frontal cortex 
(Figure 2A, B), hippocampus (Figure 2C, D) and caudo-putamen 
(Figure 2E, F). In PD cases, there was an increase in the levels of 
mGluR5 in the membrane fraction of the caudo-putamen 
(Figure 2E, F), but levels in the frontal cortex and hippocampus 
were comparable to controls (Figure 2A–D). No mGluR5 was 
detected in the cytosolic fractions. In a subset of the PD cases there 
appeared to be an inverse relationship between monomeric alpha­
syn and mGluR5 levels in the membrane fraction from the frontal 
cortex. This might be driven by the increased oligomerization of 
alpha-syn in these cases, which might correlate with the increase of 
mGluR5. Beta-arrestin was identified as a double band both in the 
membrane (Figure 2A, C and E) and cytosolic (Figure 2G, I, K) 
fractions with an approximate MW of 50 kDa. Compared to 
controls, in the DLB cases, there was a significant increase in beta­
arrestin levels in the membrane fractions from frontal cortex 
(Figure 2A, B), hippocampus (Figure 2C, D) and caudo-putamen 
(Figure 2E, F). In PD cases, compared to controls, there was an 
increase in the levels of beta-arrestin in the membrane fractions 
from the hippocampus (Figure 2C, D) and caudo-putamen 
(Figure 2E, F), but levels in the frontal cortex were comparable 
to controls (Figure 2A, B). In the cytoplasmic fractions from the 
frontal cortex beta-arrestin levels were reduced in both DLB and 
PD cases compared to controls (Figure 2G, H). In cytoplasmic 
fractions from the hippocampus, beta-arrestin levels were 
increased in both DLB and PD cases compared to controls 
(Figure 2I, J). In cytoplasmic fractions from the caudo-putamen 
region beta-arrestin levels, in comparison to controls, were 
unchanged in DLB, but higher in the PD cases (Figure 2K, L). 
Levels of mGluR5 immunolabeling are elevated in the 
brains of a-syn transgenic mice 
Two different lines of tg mice were used, the first express alpha­
syn under the PDGF promoter which favors alpha-syn accumu­
lation in the frontal cortex and limbic system with a distributions 
similar to DLB. The second express alpha-syn under the mThy-1 
promoter, which results in greater accumulation of alpha-syn in 
subcortical nuclei including the basal ganglia and midbrain, 
analogous to PD. In both non-tg and tg mice lines, mGluR5 
immunoreactivity was associated with pyramidal neurons in layers 
2–3 of the frontal cortex (Figure 3A–C), in pyramidal neurons in 
the CA3 region of the hippocampus (Figure S2A–C) and mid-
spiny neurons in the caudo-putamen (Figure S2E–G). Compared 
to non-tg mice, in PDGF-alpha-syn tg mice there was a significant 
increase in the levels of mGluR5 immunoreactivity in neurons in 
the frontal cortex (Figure 3A, B, D), hippocampus (Figure S2A, B, 
D) and caudo-putamen (Figure S2E, F, H). In the mThy1-alpha­
syn tg mice levels of mGluR5 immunoreactivity were similarly 
increased in the frontal cortex (Figure 3A, C, D), hippocampus 
(Figure S2A, C, D) and caudo-putamen (Figure S2E, G, H). In the 
control non-tg mice mild levels of beta-arrestin immunoreactivity 
were detected in pyramidal neurons in layers 2–3 and 5 of the 
frontal cortex (Figure 3E). Levels of beta-arrestin immunoreactiv­
ity were increased in the frontal cortex of PDGF- and mThy1­
alpha-syn tg mice, compared to non-tg mice (Figure 3E–H). 
By immunoblot analysis, mGluR5 was detected in the 
membrane (Figure 4A) and cytosolic (Figure 4B) fractions as a 
doublet with an estimated MW of 132 kDa. Consistent with the 
immunocytochemical studies, levels of mGluR5 in the frontal 
cortex were elevated in the membrane fractions of the alpha-syn tg 
mice compared to non-tg controls (Figure 4A, C). Beta-arrestin 
Figure 2. mGluR5, beta-arrestin and alpha-syn expression in frontal cortex, hippocampus and caudate of Control, DLB and PD 
cases. (A) Representative immunoblot of mGluR5, beta-arrestin and alpha-syn expression levels in the membrane fraction of the frontal cortex from 
control, DLB and PD cases. (B) Analysis of mGluR5 and beta-arrestin levels in the membrane fraction of the frontal cortex. (C) Representative 
immunoblot of mGluR5, beta-arrestin and alpha-syn expression levels in the membrane fraction of the hippocampus from control, DLB and PD cases. 
(D) Analysis of mGluR5 and beta-arrestin levels in the membrane fraction of the hippocampus. (E) Representative immunoblot of mGluR5, beta­
arrestin and alpha-syn expression levels in the membrane fraction of the caudate from control, DLB and PD cases. (F) Analysis of mGluR5 and beta­
arrestin levels in the membrane fraction of the caudate. (G) Representative immunoblot of mGluR5, beta-arrestin and alpha-syn expression levels in 
the cytosolic fraction of the frontal cortex from control, DLB and PD cases. (H) Analysis of mGluR5 and beta-arrestin levels in the cytosolic fraction of 
the frontal cortex. (I) Representative immunoblot of mGluR5, beta-arrestin and alpha-syn expression levels in the cytosolic fraction of the 
hippocampus from control, DLB and PD cases. (J) Analysis of mGluR5 and beta-arrestin levels in the cytosolic fraction of the hippocampus. (K) 
Representative immunoblot of mGluR5, beta-arrestin and alpha-syn expression levels in the cytosolic fraction of the caudate from control, DLB and 
PD cases. (L) Analysis of mGluR5 and beta-arrestin levels in the cytosolic fraction of the caudate. * Indicates a significant difference between DLB or 
PD cases compared to control cases (p,0.05, one-way ANOVA and post hoc Fisher). # Indicates a significant difference between DLB and PD cases 
(p,0.05, one-way ANOVA and post hoc Fisher). 
doi:10.1371/journal.pone.0014020.g002 
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Figure 3. Immunohistochemical Analysis of mGluR5, beta-arrestin and alpha-syn in the frontal cortex of alpha-syn transgenic mice. 
(A, B, C) Representative bright field microscopy images of mGluR5 immunoreactivity in the frontal cortex of non-tg, PDGF-alpha-syn and mThy1­
alpha-syn tg mice, respectively. (D) Analysis of mGluR5 immunoreactivity in the frontal cortex of non-tg, PDGF-alpha-syn and mThy1-alpha-syn tg 
mice. (E, F, G) Representative bright field microscopy images of beta-arrestin immunoreactivity in the frontal cortex of non-tg, PDGF-alpha-syn and 
mThy1-alpha-syn tg mice, respectively. (H) Analysis of beta-arrestin immunoreactivity in the frontal cortex of non-tg, PDGF-alpha-syn and mThy1­
alpha-syn tg mice. (I, J, K) Representative bright field microscopy images of alpha-syn immunoreactivity in the frontal cortex of non-tg, PDGF-alpha­
syn and mThy1-alpha-syn tg mice, respectively. (L) Analysis of alpha-syn immunoreactivity in the frontal cortex of non-tg, PDGF-alpha-syn and 
mThy1-alpha-syn tg mice. Scale bar = 30 mM. * Indicates a significant difference between alpha-syn tg mice compared to non-tg controls (p,0.05, 
one-way ANOVA and post hoc Fisher) (n = 8 cases per group). 
doi:10.1371/journal.pone.0014020.g003 
was detected as a single band at 50 kDa in both the cytosolic and 
membrane fractions. Compared to non-tg controls, in the PDGF-
and mThy1-alpha-syn tg mice the levels of beta-arrestin 
immunoreactivity were increased the neocotex in both the 
membrane (Figure 4A, C) and cytoplasmic (Figure 4B, D) 
fractions. 
mGluR5 interacts with a-syn in the brains of transgenic 
animals 
In order to identify whether the alterations in mGluR5 protein 
levels were related to transcription changes at the mRNA level, 
qPCR analysis was conducted. By qPCR, levels of mRNA were 
comparable between DLB, PD and control cases (Figure S3A) 
non-tg and PDGF- and mThy1-alpha-syn tg mice (Figure S3B), 
suggesting that transcriptional events are not involved and that 
the interaction between alpha-syn and mGluR5 occurs post­
transcription/post-translationally. Since, mGluR5 alterations by 
immunoblot were primarily detected in the membrane rather than 
cytosolic fractions and were accompanied by increased expression 
of beta-arrestin suggesting that mGluR5 localization might be 
altered by alpha-syn. Immunohistochemical double labeling with 
antibodies against alpha-syn and mGluR5 showed a small degree 
of alpha-syn co-localization with mGluR5 within the frontal cortex 
of controls (Figure 5A-C) however the degree of co-localization 
was greatly increased in the DLB (Figure 5D–F) and PD 
(Figure 5G–I) cases. Consistent with the human cases, non-tg 
mice showed a small degree of alpha-syn co-localization with 
mGluR5 within pyramidal neurons in the frontal cortex of 
(Figure 5J–L) however the degree of co-localization was greatly 
increased in the PDGF-alpha-syn tg (Figure 5M–O) and mThy1­
alpha-syn tg (Figure 5P–R) mice. 
In order to examine whether mGluR5 and alpha-syn interact 
(directly or indirectly) co-immunoprecipitation (co-IP) studies were 
conducted. When samples from the mouse brains of non-tg, 
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Figure 4. mGluR5, beta-arrestin and alpha-syn expression in frontal cortex of alpha-syn transgenic mice. (A) Representative 
immunoblot of mGluR5, beta-arrestin and alpha-syn expression levels in the membrane fraction of the frontal cortex from non-tg, PDGF-alpha-syn 
and mThy1-alpha-syn tg mice. (B) Representative immunoblot of mGluR5, beta-arrestin and alpha-syn expression levels in the cytoplasmic fraction of 
the frontal cortex from non-tg, PDGF-alpha-syn and mThy1-alpha-syn tg mice. (C) Analysis of mGluR5 and beta-arrestin levels in the membrane 
fraction of the frontal cortex. (D) Analysis of mGluR5 and beta-arrestin levels in the cytoplasmic fraction of the frontal cortex. * Indicates a significant 
difference between alpha-syn tg mice and non-tg controls p,0.05, one-way ANOVA and post hoc Fisher). # Indicates a significant difference 
between PDGF-alpha-syn and mThy1-alpha-syn tg mice (p,0.05, one-way ANOVA and post hoc Fisher)(n = 8 mice per group). 
doi:10.1371/journal.pone.0014020.g004 
PDGF-alpha-syn and mThy1-alpha-syn tg mice were immuno­
precipitated with an antibody against mGluR5 and then analyzed 
by immunoblot with an antibody against alpha-syn, the strongest 
interaction was observed in the alpha-syn tg mice when compared 
to non-tg controls (Figure 5S). No interacting bands were detected 
in control experiments with samples immunoprecipitated with a 
non-immune IgG or when the tissue sample was excluded. 
Similarly when the reverse IP was performed, by immunoprecip­
itating with an antibody against alpha-syn and then analyzing by 
immunoblot with an antibody against mGluR5, the strongest 
interaction was again observed in the alpha-syn tg mice when 
compared to non-tg controls (Figure 5T). No interacting bands 
were detected in control experiments with samples immunopre­
cipitated with a non-immune IgG. To further validate the IP, 
samples immunoprecipitated with the antibody against alpha-syn 
were analyzed with an antibody against alpha-syn. This study 
confirmed that in the samples from the alpha-syn tg mice higher 
levels of alpha-syn immunoreactivity were detected than in the 
non-tg mice (data not shown). 
Wide field mosaic analysis of alpha-syn and mGluR5 
distribution in alpha-syn transgenic mice 
Wide field mosaic imaging was conducted to examine in a more 
comprehensive manner the relationship between the distribution 
of alpha-syn and mGluR5 immunolabeling in several brain 
regions associated with rodent spatial memory and motor 
functions. (Figure S4). Patterns of alpha-syn and mGluR5 
immunolabeling were examined within the motor cortex, piriform 
cortex, four sub-regions of striatum, three regions within the 
hippocampal formation, and the substantia nigra. Alpha-syn 
immunolabeling in non-tg samples was punctate in nature, and no 
labeled cell bodies or neurites were observed in any samples. In 
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Figure 5. Co-immunoprecipitation and co-localization of alpha-syn and mGluR5. (A, D, G) Representative confocal images of alpha-syn 
immunolabeling in the frontal cortex of control, DLB and PD cases, respectively. (B, E, H) Representative confocal images of mGluR5 immunolabeling 
in the frontal cortex of control, DLB and PD cases, respectively. (C, F, I) Co-localization of alpha-syn and mGluR5 immunoreactivity in the frontal cortex 
of control, DLB and PD cases, respectively. (J, M, P) Representative confocal images of alpha-syn immunolabeling in the frontal cortex of non-tg, 
PDGF-alpha-syn tg and mThy1-alpha-syn tg mice, respectively. (K, N, Q) Representative confocal images of mGluR5 immunolabeling in the frontal 
cortex of non-tg, PDGF-alpha-syn tg and mThy1-alpha-syn tg mice, respectively. (L, O, R) Co-localization of alpha-syn and mGluR5 immunoreactivity in 
the frontal cortex of non-tg, PDGF-alpha-syn tg and mThy1-alpha-syn tg mice, respectively. (S) Representative immunoblot of the co­
immunoprecipitation of mGluR5 and alpha-syn using the anti-mGluR5 antibody for the pull-down and the alpha-syn antibody for the detection. (T) 
Representative immunoblot of the co-immunoprecipitation of mGluR5 and alpha-syn using the alpha-syn antibody for the pull-down and the anti­
mGluR5 antibody for the detection. Scale bar = 20 mM. 
doi:10.1371/journal.pone.0014020.g005 
contrast, alpha-syn immunolabeling in tg mice was noticeably 
increased, more diffuse in nature, and immunopositive cell bodies, 
dendrites and other elements in the neuropil were observed in 
many regions. In comparison, increased mGluR5 immunolabeling 
was noted in nearly identical regions. The regional statistics are 
provided in Table 2. Within the motor cortex (Figure S4B) an 
increase in alpha-syn was noted in tg versus non-tg samples. 
The mGluR5 labeling was diffuse in nature and included 
immunopositive cell bodies present within the inner granular cell 
layer. In non-tg samples we observed apparent axonal mGluR5 
immunolabeling through the cortical layers presumably on 
pyramidal cell axons. This pattern was also seen in the tg samples, 
with a noticeable increase in the amount of staining, as well as an 
extension of staining to varicosities along the axonal projections 
through the outer granular layer. Alpha-syn immunolabeling 
within tg piriform cortex (Figure S4B, C) was also more diffuse, 
with immunopositive cell bodies and neurites present within the 
cell body layers II and III. mGluR5 immunolabeling within the 
piriform cortex of non-tg animals consisted of punctate staining 
throughout the cell body layer. The levels were increased in tg 
samples and also included increased axonal staining through the 
piriform cortical cell body layers II and III. In contrast with the 
immunostaining patterns observed within the aforementioned 
cortical regions, the pattern of alpha-syn immunolabeling within tg 
striatal regions (dorsomedial, dorsolateral, ventromedial and 
ventrolateral) was punctate, and synaptic like in nature. No 
immunopositive cell bodies or neurites were observed in any 
striatal region (Figure S4B, D). Striatal mGluR5 immunolabeling 
in tg samples was increased within the neuropil, and also included 
perineuronal staining not observed in the non-tg. Sparse, small, 
punctate alpha-syn immunolabeling was found in the substantia 
nigra pars compacta (SNc) in non-tg samples. SNc immunolabel­
ing was increased in tg samples, with the addition of tyrosine 
hydroxylase-like labeled projections innervating the substantia 
nigra pars reticulata (Figure S4B). mGluR5 immunolabeling was 
increased in the SNc and consisted of labeled fibers and neurites, 
in a pattern similar to TH immunoreactivity. 
Table 2. Regional statistics and percentages for a-syn and 
mGluR5 immunolabeling for data presented in Figure S4. 
Mouse CNS
 
region alpha-syn Immunolabeling mGluR5 Immunolabeling
 
Motor Cortex +95.7% 
p,0.05, F(1,11) = 8.99 
+120.8% 
p,0.01, F(1,11) = 20.64 
Piriform Cortex +5.6% 
n.s., F(1,9) = 0.28 
+53.13% 
P,0.01, F(1,9) = 51.59 
Dorsomedial 
Striatum 
+275.6% 
p,0.01, F(1,14) = 17.60 
+159.6% 
p,0.01, F(1,14) = 55.63 
Dorsolateral 
Striatum 
+199.6% 
p,0.01, F(1,14) = 17.22 
+150.6% 
p,0.01, F(1,14) = 100.54 
Ventromedial 
Striatum 
+42.7% 
p,0.05, F(1,14) = 8.57 
+62.3% 
p,0.05, F(1,14) = 4.77 
Ventrolateral 
Striatum 
+112.2% 
p,0.01, F(1,14) = 8.04 
+98.5% 
p,0.01, F(1,14) = 38.27 
Substantia Nigra +55.5% 
p,0.01, F(1,11) = 7.41 
+59.26% 
p,0.05, F(1,11) = 7.41 
CA1 region +178.5 
p,0.01, F(1,10) = 103.95 
+51.52% 
n.s., F(1,10) = 4.57 
CA3 region +97.8% 
p,0.05, F(1,7) = 8.97 
+259.3% 
p,0.01, F(1,7) = 42.53 
Dentate Gyrus +51.4% 
p,0.05, F(1,17) = 6.70 
+80.7% 
p,0.01, F(1,17) = 32.59 
doi:10.1371/journal.pone.0014020.t002 
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Within the hippocampal formation we examined alpha-syn and 
mGluR5 immunolabeling within CA1, CA3 and dentate gyrus. 
Within the CA1 field of non-tg samples, alpha-syn immunolabel­
ing within the neuropil was largely confined to the area 
immediately surrounding the pyramidal cell layer. Within the 
pyramidal cell layer of CA1, alpha-syn immunolabeling was 
present on axonal projections and surrounding cell bodies. 
mGluR5 labeling within the CA1 largely followed the pattern of 
alpha-syn immunoreactivity. Axonal mGluR5 staining was also 
evident through the extent of the pyramidal cell layer with labeled 
axonal projections towards the stratum radiatum (Figure S4B). 
Within the CA3 region of non-tg samples, punctate alpha-syn 
immunolabeling was largely confined to the area adjacent to the 
stratum lucidum. An expansion of alpha-syn immunoreactivity 
was seen in tg samples with an increase in staining within the 
neuropil, and including many immunopositive cell bodies within 
the stratum lucidum (Figure S4B). In non-tg samples, the pattern 
of larger punctate mGluR5 immunolabeling corresponded to the 
distribution of alpha-syn immunoreactivity. Like alpha-syn 
immunoreactivity in tg animals, mGluR5 immunolabeling was 
increased in tg mice throughout the neuropil and surrounded cell 
bodies within the stratum lucidum. 
Alpha-syn immunolabeling was sparse within all sub-regions of 
non-tg dentate gyrus, and was substantially increased within 
molecular layers, hilus and supra- and infrapyramidal blades of the 
dentate gyrus (Figure S4B). This included punctate labeling in the 
neuropil surrounding cell bodies and cytoplasmic labeling of cells 
within the hilus. mGluR5 labeling of non-tg dentate gyrus 
included labeling of collateral varicosities within the hilus, diffuse 
labeling of the neuropil in the molecular layers, and minimal 
axonal-like labeling through cell body layers of the suprapyramidal 
and infrapyramidal blades. The intensity of mGluR5 labeling was 
increased in tg samples and included labeling of intracytoplasmic 
regions of large neuronal cell bodies, with an approximate shape 
and size appropriate for interneurons and main apical dendrites 
within the hilus. 
Increased mGluR5 signaling in DLB/PD and alpha-syn 
transgenic mice 
In order to investigate whether the increased mGluR5 level in 
the DLB and PD cases and in the alpha-syn tg mice was associated 
with a concomitant increase in the levels of downstream signaling 
components, levels of total and phosphorylated ERK, Elk–1 and 
CREB were examined in the cytoplasmic and membrane fractions 
from the frontal cortex. In the membrane fraction ERK activation 
(ratio of pERK/tERK) was increased in the DLB and PD cases in 
comparison to the control cases (Figure 6A, E). Elk-1 activation 
(ratio of pElk-1/tElk-1) was increased in the membrane fraction 
from the DLB cases but not PD cases, when compared to controls. 
(Figure 6A, G). CREB activation (ratio of pCREB/tCREB) was 
increased in the nuclear fraction from the DLB and PD cases when 
compared to controls (Figure 6C, I), In the cytoplasmic fraction, 
both DLB and PD cases displayed increased ERK activation (ratio 
pERK/totalERK) compared to control cases (Figure 6B, F). No 
significant differences in Ekl-1 activation were noted between DLB 
or PD cases and controls (Figure 6B, H). CREB activation was 
decreased in the soluble fraction from both DLB and PD when 
compared to control cases (Figure 6D, J). A similar immunoblot to 
investigate downstream signaling components was conducted on 
the membrane, cytosolic and nuclear fractions from the frontal 
cortex of non-tg and alpha-syn tg mice (Figure 7). 
The ERK activation was increased in the mThy-1-alpha-syn tg 
mice in both the membrane (Figure 7A, E) and cytoplasmic 
(Figure 7B, F) fractions in comparison to non-tg controls, however 
it did not differ between PDGF-alpha-syn tg mice and non-tg 
controls on either fraction (Figure 7A, B, E, F). The membrane 
fraction both the PDGF-alpha-syn and mThy1-alpha-syn tg mice 
displayed increased levels of Elk-1 activation in comparison to 
non-tg controls (Figure 7A, G). No Elk-1 activation was detected in 
the cytoplasmic fraction (Figure 7B, H). CREB activation was 
increased in the PDGF-alpha-syn and mThy1-alpha-syn tg mice in 
the nuclear fraction compared to non-tg controls (Figure 7C, I), 
however in the soluble fraction CREB activation was only 
increased in the mThy1-alpha-syn tg mice when compared to 
non-tg controls (Figure 7D, J). 
Motor deficits in the pole test apparatus in alpha-syn 
transgenic mice are ameliorated by the mGluR5 inhibitor 
MPEP 
In the tg mice there is considerable accumulation of alpha-syn 
in the caudo-putamen region that is accompanied by motor 
deficits in the pole test. Since it is possible that increased 
expression of mGluR5 in mid-spine neurons as shown here might 
play a role in the motor deficits, non-tg and alpha-syn tg mice were 
treated with the mGluR5 antagonist MPEP and tested in the pole 
test. This behavioral test requires the subjects to grip and traverse 
the pole requiring motor strength and coordination [54,63]. The 
stringent test parameters help to ensure that tg deficits are not 
obscured by compensatory responses (e.g. incomplete turns prior to 
descending the pole apparatus). Compared with non-tg mice, 
alpha-syn tg mice were impaired in ability to negotiate the pole 
apparatus as evidenced by a significant longer T-Turn time 
(Baseline, Figure 8A). 
To assess whether mGluR5 antagonism could ameliorate the 
pole test behavioral deficit observed in the tg animals, mice were 
treated with the mGluR5 antagonist MPEP. Following treatment 
with MPEP T-Turn was comparable between the non-tg and 
alpha-syn tg mice (MPEP Treatment, Figure 8A). Analysis of the 
difference between the first and second test days revealed an 
improvement in T-Turn times of the alpha-syn tg mice as 
indicated by significant improvement in the success ratio from the 
first test to second test session (F(1,6) = 6.40; p = 0.0447). When the 
mice were tested a day after the MPEP treatment (Re-test, no 
treatment, Figure 8A), once more alpha-syn tg mice displayed 
impaired performance in the pole test when compared to the non­
tg controls (F(1,6) = 18.498; p = 0.0051). 
The spatial memory deficits in alpha-syn transgenic mice 
are ameliorated by the mGluR5 inhibitor MPEP 
Though motor deficits are more often highlighted, cognitive 
deficits associated with alpha-syn accumulation in the limbic 
system have also been reported in patients with Parkinson’s disease 
dementia and dementia with LB’s [56]. These alterations might be 
associated with the increased expression of mGluR5 in the frontal 
cortex and hippocampus of the alpha-syn tg mice. To investigate 
this possibility, mice were tested in the water maze and treated 
with the mGluR5 antagonist MPEP. During the training period of 
the test, repeated measures ANOVA revealed no significant 
differences among the groups path length (F(1,12) = 2.294, 
p = 0.1557 and F(1,6) = 0.500, p = 0.8060). During the spatial 
learning period of the test with the platform submerged, vehicle 
treated alpha-syn tg mice displayed performance deficits when 
compared to the vehicle treated non-tg controls (Figure 8B). In 
contrast, MPEP treatment improved the behavioral performance 
of the alpha-syn tg compared to the vehicle treated alpha-syn tg 
mice (Figure 8C). The MPEP treated alpha-syn tg mice 
performance was similar to the non-tg controls. In the last day 
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Figure 6. Immunoblot analysis of ERK, Elk-1 and CREB activity in Control, DLB and PD cases. (A) Representative immunoblot of phospho-
ERK (pERK), total ERK (tERK) phospho-ELK-1 (pELK-1) and total ELK-1 (tELK-1) expression levels in the membrane fraction from the frontal cortex of 
control, DLB and PD cases. (B) Representative immunoblot of pERK, tERK, pELK-1 and tELK-1 expression in the cytoplasmic fraction from the frontal 
cortex of control, DLB and PD cases. (C) Analysis of ERK activity (pERK/tERK ratio) in the membrane fraction. (D) Analysis of ERK activity (pERK/tERK 
ratio) in the cytosolic fraction. (E) Analysis of Elk-1 activity (pElk-1/tElk-1 ratio) in the membrane fraction. (F) Analysis of Elk-1 activity (pElk-1/tElk-1 
ratio) in the cytosolic fraction. (G) Representative immunoblot of phospho-CREB (pCREB) and total CREB (tCREB) in the nuclear fraction from the 
frontal cortex of control, DLB and PD cases. (H) Representative immunoblot of pCREB and tCREB in the soluble fraction from the frontal cortex of 
control, DLB and PD cases. (I) Analysis of CREB activity in the nuclear fraction. (J) Analysis of CREB activity in the soluble fraction. * Indicates a 
significant difference between DLB or PD cases compared to control cases. (p,0.05, one-way ANOVA and post hoc Fisher) (n = 8 cases per group). 
doi:10.1371/journal.pone.0014020.g006 
of testing the platform was removed. The probe test indicated a 
significant main effect of the genotype on entrances and passes into 
target zone (F(1,12) = 6.649, p = 0.0242). In contrast, alpha-syn tg 
mice treated with MPEP exhibited a similar number of entrances 
and passes into target zone when compared to the non-tg controls. 
MPEP treatment had no effect on the performance of the non-tg 
mice (Figure 8D). 
A subsequent trial in which the platform was visible, confirmed 
that both groups were able to locate the platform via visual 
sighting. These results indicate that the deficit in ability to locate 
the correct zone, seen in the alpha-syn tg mice, is not attributable 
to a visual or gross motor deficit, but is instead likely to be a 
consequence of a memory or spatial navigation defect. 
Discussion 
Excitoxicity has been proposed to play a role in the mechanisms 
of neurodegeneration in DLB and PD. The present study showed 
that alterations in the levels of mGluR5 in selected brain regions in 
patients with DLB or PD and in alpha-syn transgenic mice might 
be involved. Specifically, mGluR5 was increased in the frontal 
cortex, hippocampus and caudate in DLB in and in the caudate in 
PD, these areas correspond closely with areas displaying increased 
alpha-syn accumulation. The results of this study are consistent 
with previous studies that have shown increased expression or 
activation of glutamate receptors in the acute neurotoxicity rodent 
[43] and primate [64] models of PD and in other neurodegen­
erative disorders with protein accumulation such as Amyotrophic 
lateral sclerosis (mGluR5; [65]), Down’s syndrome (mGluR5; 
[66]), and AD (mGluR2/3; [32,67,68,69]). However, our study is 
the first to document alterations in mGluR5 in human DLB and 
PD cases and in alpha-syn tg mice. 
The important of metabotropic glutamate receptors, particu­
larly mGluR5, in neurodegenerative disorders is underlined by 
recent work suggesting that excitotoxicity mediated by metabo­
tropic receptors may be a key mechanism underlying neurode­
generation [70,71] and by recent experimental therapies based in 
the development of mGluR5 antagonists [71,72,73,74]. Consistent 
with this proposed role of mGluR5 in excitotoxicity and the 
potential therapeutic use of mGluR5 antagonists we show that 
when the alpha-syn tg mice were treated with the mGluR5 
antagonist MPEP their motor and learning/memory deficits were 
ameliorated. This is in agreement with previous studies showing 
that mGluR5 inhibitors reduce the motor alterations in rodent 
models challenged with MPTP or 6-OH DOPA [75,76,77,78] and 
recent studies in primates showing that MPEP and another 
mGluR5 antagonist such as MTEP (3-((2-Methyl-4-thiazolyl)ethy­
nyl)pyridine) has beneficial anti-dyskinetic effects in L-Dopa­
treated MPTP monkeys [79,80]. Moreover, co-administration of 
adenosine 2A and mGluR5 antagonists reverses the behavioral 
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Figure 7. Immunoblot Analysis of ERK, Elk-1 and CREB activity in alpha-syn transgenic mice. (A) Representative immunoblot of phospho-
ERK (pERK), total ERK (tERK) phospho-ELK-1 (pELK-1) and total ELK-1 (tELK-1) expression levels in the membrane fraction from the frontal cortex of 
non-tg, PDGF-alpha-syn and mThy1-alpha-syn tg mice. (B) Representative immunoblot of pERK, tERK, pELK-1 and tELK-1 expression in the 
cytoplasmic fraction from the frontal cortex of non-tg, PDGF-alpha-syn and mThy1-alpha-syn tg mice. (C) Analysis of ERK activity (pERK/tERK ratio) in 
the membrane fraction. (D) Analysis of ERK activity (pERK/tERK ratio) in the cytosolic fraction. (E) Analysis of Elk-1 activity (pElk-1/tElk-1 ratio) in the 
membrane fraction. (F) Analysis of Elk-1 activity (pElk- 1/tElk-1 ratio) in the cytosolic fraction. (G) Representative immunoblot of phospho- CREB 
(pCREB) and total CREB (tCREB) in the nuclear fraction from the frontal cortex of non-tg, PDGF-alpha-syn and mThy1-alpha-syn tg mice. (H) 
Representative immunoblot of pCREB and tCREB in the soluble fraction from the frontal cortex of non-tg, PDGF-alpha-syn and mThy1-alpha-syn tg 
mice. (I) Analysis of CREB activity in the nuclear fraction. (J) Analysis of CREB activity in the soluble fraction. * Indicates a significant difference between 
alpha-syn tg mice and non-tg controls p,0.05, one-way ANOVA and post hoc Fisher). # Indicates a significant difference between PDGF-alpha-syn 
and mThy1-alpha-syn tg mice (p,0.05, one-way ANOVA and post hoc Fisher)(n = 8 mice per group). 
doi:10.1371/journal.pone.0014020.g007 
deficits in a reserpinized mouse model of PD [51]. In addition to 
the effects at reducing motor alterations, MPEP has been shown to 
reduce the visuo-spatial discrimination deficit induced by bilateral 
dopamine lesion of the striatum [81]. This same treatment 
increased contralateral turning induced by L-DOPA in mice 
bearing unilateral 6-OHDA lesion suggesting that mGluR5 
blockade may also have beneficial effects on cognitive deficits 
induced by dopamine depletion [81]. Therefore, both neurotoxic 
and transgenic models of parkinsonism support the possibility that 
antagonism of mGluR5 might be potentially beneficial in the 
treatment of DLB and PD patients. 
mGluR5 has attracted considerable interest due to its abundant 
expression in the frontal cortex, limbic system, and caudo-putamen 
[37]—brain regions selectively affected in PD. The vulnerability of 
selected neuronal populations in PD and DLB patients has been 
linked to glutamate-mediated excitotoxicity [82]. Consistent with 
this, the double labeling and mosaic analysis showed that there was 
some regional specificity to the increased levels of mGluR5 that 
corresponded to the areas of greater a-syn accumulation and 
neurodegeneration. For example, in the DLB cases mGluR5 was 
elevated in the frontal cortex, limbic system and putamen, while in 
the PD cases the increase was more prominent in the putamen. In 
the PDGF-alpha-syn tg mice mGluR5 increases were more 
prominent in the frontal cortex and limbic system while in the 
mThy1-alpha-syn tg mice mGluR5 was also elevated in the 
striatum. Of the affected areas mGluR5 was found in pyramidal 
neurons in the deeper layers of the frontal cortex, CA3 region of the 
hippocampus and mid-spiny neurons in the striatum. These are all 
neuronal populations and brain regions selectively affected in DLB 
and PD patients [11,83,84,85] suggesting that mGluR5 might play 
a role in the mechanisms of selective neuronal vulnerability in 
disorders with alpha-syn accumulation. 
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Figure 8. Motor and learning/memory deficits in alpha-syn transgenic mice are ameliorated by MPEP administration. (A) Pole test 
performance (T-Turn) of the non-tg and PDGF-alpha-syn tg mice, at baseline, following MPEP treatment and at re-test (no treatment). (B) Morris water 
maze performance of vehicle-treated non-tg and PDGF-alpha-syn tg mice. (C) Morris water maze performance of MPEP- treated PDGF-alpha-syn tg 
mice. (D) Morris water maze performance of MPEP-treated non-tg mice. * Indicates a significant difference between groups examined (p,0.05, one-
way ANOVA and post hoc Fisher) (n = 8 per group). 
doi:10.1371/journal.pone.0014020.g008 
The precise mechanisms by which alpha-syn accumulation in 
DLB, PD and tg models might lead to the increase mGluR5 is not 
completely clear. However the alterations in mGluR5 are most 
likely post-translational since levels of mGluR5 mRNA did not 
differ between control and DLB or PD cases or between non-tg 
and alpha-syn transgenic mice. Thus, it is possible that alpha-syn 
interacts with mGluR5 to alter the distribution of these receptors 
at the cell membrane of particular cell populations, which may 
lead to an increase in mGluR5 activity and glutamate-mediated 
excitotoxicity in specific brain regions. In support of this 
interaction hypothesis we showed a greater degree of mGluR5 
and alpha-syn co-immunoprecipitation in the alpha-syn tg mice 
compared to non-tg mice and a greater accumulation of mGluR5 
in the membrane fractions from DLB or PD cases and in alpha­
syn tg mice compared to control cases or non-tg mice. Moreover 
the increase in mGluR5 was accompanied by an increase in beta­
arrestin, a protein involved in the internalization and recycling of 
the receptor. Taken together, these results suggest that accumu­
lation of alpha-syn might alter mGluR5 localization at the cell 
surface, allowing a greater proportion to remain membrane-
associated rather than being recycled. 
If this is the case, then it is also possible that increased presence 
of the receptor at the cell surface may lead to over activation of the 
downstream mGluR5 signaling pathway. mGluR5 is a Group I 
metabotropic glutamate receptor that couples with phospholipase 
C (PLC) via Gq-like G-proteins. PLC activates protein kinase-C 
(PKC) activation via diacylglycerol and PKC goes on to 
phosphorylate and activate ERK, which activates ElK-1. PLC 
additionally activates inositol 1,4,5-trisphosphate (IP3) resulting in 
the release of calcium from intracellular stores such as the 
endoplasmic reticulum. This calcium in turn activates a number of 
calcium-responsive proteins such as those involved in the calcium/ 
calmodulin/calmodulin kinase (CaM kiinase) cascade including 
CaMKinase I and IV which phosphorylate cyclic-AMP response 
element-binding (CREB) and activate gene expression [86]. 
We demonstrate that the increased expression of mGluR5 in 
DLB, PD and alpha-syn tg mice is accompanied by an increase 
activation of down-stream signaling pathway components includ­
ing ERK, Elk-1 and CREB. Dysregulated calcium homeostasis has 
been linked to a number of neurodegenerative diseases including 
PD and AD [87] and as over activation of the mGluR5 signaling 
pathway may also contribute to increases in intracellular calcium it 
might play a role in mGluR5-mediated selective vulnerability. 
In addition to the increased expression and over activation of 
mGluR5, alpha-syn has been reported to interact with individual 
components of the mGluR5 signaling pathway including ERK 
and Elk-1 [88,89], this is supported by the detection of ERK, Elk-1 
and alpha-syn in Lewy Body aggregates. Iwata and colleagues 
have demonstrated that in vitro over expression of alpha-syn 
reduces ERK-1/2 phosphorylation and activation of ERK-1/2 
signaling, eventually resulting in cell death [90]. Therefore it is 
possible that alpha-syn may modulate mGluR5 activity both 
directly - by increasing cell surface concentrations of the receptor 
itself, as evidenced by the concomitant increase in levels of beta­
arrestin that may serve to keep greater proportions of the receptor 
at the cell surface rather than being recycled and indirectly - by 
binding to the downstream signaling components of the mGluR5 
pathway. 
Taken together the results from study this support the notion 
that alpha-syn may directly interact with mGluR5 resulting in its 
over activation and suggest that this over activation may 
contribute to excitotoxic cell death in selected neuronal popula-
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tions expressing higher levels of mGluR5. These results also 
highlight the potential therapeutic importance of mGluR5 
antagonists in disorders characterized by alpha-syn accumulation. 
Supporting Information 
Figure S1 Hippocampal and caudate levels of mGluR5 in
 
Control, DLB and PD cases. (A–C) Representative images of
 
mGluR5 immunoreactivity in the CA2/3 of the hippocampus
 
from control, DLB and PD cases respectively, analyzed in (D). (E–
 
G) Representative images of mGluR5 immunoreactivity in the
 
caudate from control, DLB and PD cases respectively, analyzed in
 
(H). Scale bar = 50 mM * Indicates a significant difference
 
between DLB or PD cases compared to control cases (p,0.05,
 
one-way ANOVA and post hoc Fisher). # Indicates a significant
 
difference between DLB and PD cases (p,0.05, one-way ANOVA
 
and post hoc Fisher) (n = 8, case per group).
 
Found at: doi:10.1371/journal.pone.0014020.s001 (2.38 MB TIF)
 
Figure S2 Hippocampal and caudate levels of mGluR5 in
 
alpha-syn transgenic mice. (A–C) Representative images of
 
mGluR5 immunoreactivity in the CA2/3 of the hippocampus of
 
non-tg, PDGF-alpha-syn and mThy1-alpha-syn tg mice respec­
tively, analyzed in (D). (E–G) Representative images of mGluR5
 
immunoreactivity in the caudate of non-tg, PDGF-alpha-syn and
 
mThy1-alpha-syn tg mice respectively, analyzed in (H). * Indicates
 
a significant difference between alpha-syn tg mice compared to
 
non-tg controls (p,0.05, one-way ANOVA and post hoc Fisher).
 
Found at: doi:10.1371/journal.pone.0014020.s002 (2.34 MB TIF)
 
Figure S3 mGluR5 mRNA levels in Control, DLB and PD cases
 
and alpha-syn transgenic mice. (A) Quantitative real-time PCR
 
(qPCR) analysis of mGluR5 mRNA levels in Control, DLB and
 
PD cases. (B) qPCR analysis of mGluR5 mRNA levels in non-tg,
 
PDGF-alpha-syn tg and mThy1-alpha-syn tg mice.
 
Found at: doi:10.1371/journal.pone.0014020.s003 (0.27 MB TIF)
 
Figure S4 High-resolution, large-scale maps of alpha-syn and
 
mGluR5 in alpha-syn transgenic mice. (A) Representative confocal
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